Viva Biotech's 2025 Annual Report Highlights AI Advancements in Drug Discovery and CDMO Growth Viva Biotech recently announced impressive 2025 annual results highlighting significant advancements in AI-driven drug discovery and CDMO product scaling.

Viva Biotech's 2025 Annual Report Highlights AI Advancements in Drug Discovery and CDMO Growth #China #Shanghai #Drug_Discovery #CDMO #Viva_Biotech

Samsung Biologics Honored for Sustainability at CDMO Leadership Awards 2026 Samsung Biologics has been awarded the Sustainability Leadership Award at the 2026 CDMO Leadership Awards, highlighting their commitment to sustainable practices.

Samsung Biologics Honored for Sustainability at CDMO Leadership Awards 2026 #Sustainability #South_Korea #Samsung_Biologics #Incheon #CDMO

Cambrex Marks Significant Expansion in U.S. and Europe with New Facilities Cambrex, a top global CDMO, has announced major expansions in the U.S. and Europe, including a new manufacturing plant in Iowa and enhancements in Italy.

Cambrex Marks Significant Expansion in U.S. and Europe with New Facilities #United_States #Cambrex #CDMO #Charles_City,_Iowa #Pharmaceutical_Contract_Manufacturing

Cambrex Takes Major Steps in Expanding US and European Manufacturing Capacities Cambrex, a leading global CDMO, announces the completion of technical studies for a new manufacturing plant in Iowa as part of its expansion efforts.

Cambrex Takes Major Steps in Expanding US and European Manufacturing Capacities #United_States #pharmaceuticals #Cambrex #CDMO #Charles_City

Cambrex Accelerates Expansion Efforts in the US and Europe with New Manufacturing Facilities Cambrex announces the completion of initial engineering studies for a new pharmaceutical manufacturing plant in Iowa and ongoing investments in Europe.

Cambrex Accelerates Expansion Efforts in the US and Europe with New Manufacturing Facilities #USA #pharmaceuticals #Cambrex #CDMO #Charles_City

Scinai Immunotherapeutics Unveils Its Expanded CDMO Capabilities and Immunology Pipeline at BIO-Europe Spring 2026 Scinai Immunotherapeutics Limited is showcasing its enhanced CDMO platform and immunology pipeline at BIO-Europe Spring 2026, marking a pivotal moment for the biopharmaceutical company.

Scinai Immunotherapeutics Unveils Its Expanded CDMO Capabilities and Immunology Pipeline at BIO-Europe Spring 2026 #Scinai_Immunotherapeutics #Israel #Jerusalem #CDMO #BIO-Europe_Spring

Incyte’s Lung Cancer Expansion Bid Thwarted by Issues at Novo’s Catalent-Acquired Site Incyte is looking to expand the use of its PD-1 blocker Zynyz to treat non-small cell lung cancer. The FDA’s rejection did not flag problems with the drug’s efficacy or safety.

Novo's issues with the US manufacturing site it acquired from Catalent continue, this time hitting Incyte’s bid to expand its PD-1 blocker Zynyz into lung cancer

www.biospace.com/fda/incytes-...

#pharma #manufacturing #CDMO

Neuland Laboratories to open Hyderabad commercial peptide facility The CDMO’s Module 1 commercial production module to be operational by summer 2026 as part of its planned phased expansion.

Neuland Laboratories to open Hyderabad commercial peptide facility, with the CDMO’s new commercial production module expected to be operational by summer 2026.

www.europeanpharmaceuticalreview.com/news/272047/...

#pharma #CDMO #CDMOs

Charles River Laboratories parts ways with its CDMO business Aims to further strengthen and broaden its portfolio in order to drive long-term growth, greater efficiency and operational excellence.

Charles River Laboratories parts ways with its contract manufacturing business and hatches plans to sell some of its European discovery services

www.europeanpharmaceuticalreview.com/news/271717/...

#pharma #manufacturing #CDMO #CDMOs

Avid Bioservices Unveils New Early Phase Center of Excellence in Costa Mesa, California Avid Bioservices has inaugurated a new Early Phase Center of Excellence in Costa Mesa, California, enhancing its biologics development capabilities significantly.

Avid Bioservices Unveils New Early Phase Center of Excellence in Costa Mesa, California #USA #Avid_Bioservices #Costa_Mesa #CDMO #Biologics

Akums Expands Presence in Europe and UK: India's Largest CDMO Boosts Global Reach Akums Drugs & Pharmaceuticals Ltd., India's top CDMO, enhances its global footprint with EU GMP certification and aims for growth in Europe and UK.

Akums Expands Presence in Europe and UK: India's Largest CDMO Boosts Global Reach #India #New_Delhi #CDMO #EU_GMP #Akums_Drugs

Akums Expands Global Footprint with EU GMP Certification in Europe and UK Akums Drugs & Pharmaceuticals Ltd., India's largest CDMO, strengthens its global presence by obtaining EU GMP certification, targeting European and UK markets.

Akums Expands Global Footprint with EU GMP Certification in Europe and UK #India #New_Delhi #pharmaceuticals #CDMO #Akums_Drugs

Akums's Expansion into Europe: A Milestone for India's Largest CDMO Akums Drugs & Pharmaceuticals is making strides in Europe by securing EU certification, enhancing its international reach in the pharmaceutical market.

Akums's Expansion into Europe: A Milestone for India's Largest CDMO #India #New_Delhi #pharmaceuticals #CDMO #Akums_Drugs

Why Pharma can’t ignore friendshoring in supply chain Bora Pharma exec, J.D. Mowery, discusses how geopolitical shifts are reshaping pharmaceutical manufacturing and supply chain strategy.

J.D. Mowery of Bora Pharmaceuticals explains why "friendshoring" is more than a buzzword—it's about patient-centric supply chains, geopolitical resilience, and rethinking manufacturing strategy for 2026 and beyond.
#News #Pharma #SupplyChain #Friendshoring #CDMO #Manufacturing #BoraPharmaceuticals

Why Pharma can’t ignore friendshoring in supply chain Bora Pharma exec, J.D. Mowery, discusses how geopolitical shifts are reshaping pharmaceutical manufacturing and supply chain strategy.

J.D. Mowery of Bora Pharmaceuticals explains why "friendshoring" is more than a buzzword—it's about patient-centric supply chains, geopolitical resilience, and rethinking manufacturing strategy for 2026 and beyond.
#News #Pharma #SupplyChain #Friendshoring #CDMO #Manufacturing #BoraPharmaceuticals

This week on EPR: J&J’s manufacturing investment, FDA’s trial rule change and approvals for GSK and Amgen Welcome to EPR’s latest LinkedIn newsletter. Each week we share news, analysis and resources from across the biopharma sector, with a focus on the industry’s manufacturing and research work.

J&J’s US investment in cell therapy manufacturing, GSK and Amgen product approvals, the FDA’s clinical trial rule changes and more feature in the latest issue of EPR's weekly newsletter.

www.linkedin.com/pulse/week-e...

#pharma #manufacturing #CDMO #CDMOs

Rois appoints Kimberlee Steele as Chief Commercial Officer She joins the Madrid-headquartered contract development and manufacturing organisation from SHL Medical.

Spanish CDMO Rois has appointed Kimberlee Steele as Chief Commercial Officer

www.europeanpharmaceuticalreview.com/news/271424/...

#pharma #CDMO

医療機器CDMO市場分析（2032年） 医療機器CDMO市場規模は2023年に116億8,000万米ドルと推定されています。医療機器CDMO市場産業は2024年の137億4,000万米ドルから2032年までに504億米ドルに成長すると予想されています。

🏭 Medical device CDMOs enable scalable innovation & manufacturing. Report: www.wiseguyreports.com/ja/reports/m... #CDMO

Rottendorf and Corealis collaborate on OSD manufacturing The two CDMOs sign an alliance to offer an integrated early-development offering and accelerated commercial pathway.

CDMOs Rottendorf Pharma and Corealis Pharma sign on oral solid dose manufacturing and development alliance

www.europeanpharmaceuticalreview.com/news/271295/...

#pharma #CDMO #manufacturing #OSD

Dr Veit Bergendahl to join Rentschler Biopharma as COO New operations lead brings over twenty years of biopharma experience to the CDMO’s Laupheim and Milford sites.

Dr Veit Bergendahl to join Rentschler Biopharma as Chief Operating Officer, bringing over twenty years of biopharma experience to the CDMO’s Laupheim and Milford sites

www.europeanpharmaceuticalreview.com/news/271254/...

#pharma #CDMO

Fujifilm inaugurates expanded £400m UK biomanufacturing site The CDMO’s investment in the North-East based site expansion supports UK production of medicines and vaccines.

Fujifilm Biotechnologies expands its UK manufacturing and process development presence, with the CDMO investing £400 million in its North East of England site

www.europeanpharmaceuticalreview.com/news/271245/...

#pharma #CDMO #manufacturing

Fresenius Kabi and Phlow onshore US epinephrine manufacturing The collaboration covers domestic manufacture of the essential medicine's active pharmaceutical ingredients (APIs) and finished doses.

Fresenius Kabi and Phlow onshore US epinephrine manufacturing in a collaboration that covers the essential medicine’s active pharmaceutical ingredients (APIs) and finished doses

www.europeanpharmaceuticalreview.com/news/271209/...

#pharma #manufacturing #CDMO

Vetter Pharma outlines plans for new manufacturing site in Germany The CDMO is also adding to its footprint with a new US aseptic clinical production facility in Illinois, construction of which began recently.

Vetter Pharma outlines plans for a new manufacturing site in Germany as the CDMO's work on a new US aseptic clinical production facility progresses

www.europeanpharmaceuticalreview.com/news/271040/...

#pharma #CDMO #manufacturing

Advanced Therapy Medicinal Products Cdmo Market By 2035 Advanced Therapy Medicinal Products Cdmo Market growth is projected to reach 134.73 USD billion, at a 14.64% CAGR by driving industry size, share, top company analysis, segments research, trends and f...

Cell & gene therapy growth is driving demand in the ATMP CDMO Market. Explore trends: www.marketresearchfuture.com/reports/adva...
#CellTherapy #GeneTherapy #CDMO

Ardena divests Södertälje drug substance site to Nanologica The CDMO and CRO’s Swedish API facility will now operate as a Nanologica subsidiary, reverting to its original name Syntagon.

Ardena divests Swedish API site to Nanologica, with the facility reverting to its original name Syntagon

www.europeanpharmaceuticalreview.com/news/270955/...

#pharma #CDMO

Founded in 2005, Porton Pharma Solutions is a world-class CDMO, empowering global clients across the drug development spectrum—from Small Molecules and Biologics to Advanced Therapy Medicinal Products (ADCs, PDCs, RDCs). Their expertise from pre-clinical to commercialization is an invaluable asset to our ecosystem. 👏 Entrepreneurs: This is your chance to pitch in front of industry giants and top-tier VCs. Don't miss this marketplace opportunity! 🔗 Apply/Register here: https://lnkd.in/ePTt9247

Another industry leader is on board!

We are thrilled to announce that Porton Pharma Solutions Ltd. (SZSE: 300363), a publicly listed company, has joined us as a key supporter for our 2026 Biomedical Pitch Competition.

#Biotech #Startups #CDMO #VentureCapital #Biomedical #PitchCompetition #BCIC

Piramal Pharma Reports Q3 FY26 Results Amid Challenges, Signs of Recovery Piramal Pharma Limited has announced its standalone and consolidated financial results for Q3 and 9M FY26, reflecting both challenges and early signs of recovery.

Piramal Pharma Reports Q3 FY26 Results Amid Challenges, Signs of Recovery #India #Mumbai #CDMO #Piramal_Pharma #Kenalog

Samsung Biologics Unveils Impressive Financial Results for FY 2025 Samsung Biologics reports strong financial performance in FY 2025, showcasing resilience and growth through strategic expansions and strong client demand.

Samsung Biologics Unveils Impressive Financial Results for FY 2025 #South_Korea #pharmaceutical #Samsung_Biologics #Incheon #CDMO

Cell therapy-focused CDMO Kincell Bio has elevated Bruce Thompson to President and Chief Technology Officer in a trio of promotions that also sees new roles for Melodie Bryce and Matt Haines.

www.europeanpharmaceuticalreview.com/news/270466/...

#pharma #CDMO

ReiThera on vaccines and remaining nimble around emerging threats As vaccines are buffeted by political pressures, the CDMO discussed its growth approach and some of its key collaborations.

ReiThera on vaccines and remaining nimble around emerging threats - as vaccines continued to be buffeted by political pressures, the CDMO discussed its growth approach, key collaborations and some of its successes

www.europeanpharmaceuticalreview.com/article/2694...

#pharma #CDMO #vaccines